FDA Inspection 1063039 - HomeChoice Partners dba BioScript Infusion Services - August 17, 2018

FDA Inspection 1063039 for HomeChoice Partners dba BioScript Infusion Services on August 17, 2018. Classification: Official Action Indicated (OAI).

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA Inspection 1063039 for HomeChoice Partners dba BioScript Infusion Services on August 17, 2018. Classification: Official Action Indicated (OAI).

Violation Codes

21 CFR 211.42(c)(10)(v)

21 CFR 211.56(a)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

HomeChoice Partners dba BioScript Infusion Services

Inspection Date

August 17, 2018

Product Type

Drugs

Office

Center for Drug Evaluation and Research

ID: b167f834-d345-4fa2-8d54-b63f004a7e30

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox